NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 165 filers reported holding NOVOCURE LTD in Q2 2018. The put-call ratio across all filers is 0.23 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $246,510 | -48.8% | 5,940 | -25.8% | 0.00% | -40.0% |
| Q1 2023 | $481,300 | -34.4% | 8,003 | -20.0% | 0.01% | -44.4% |
| Q4 2022 | $734,013 | -4.2% | 10,007 | -0.7% | 0.01% | -10.0% |
| Q3 2022 | $766,000 | +20.6% | 10,079 | +10.3% | 0.01% | +25.0% |
| Q2 2022 | $635,000 | -18.2% | 9,138 | -2.4% | 0.01% | 0.0% |
| Q1 2022 | $776,000 | +74.4% | 9,366 | +58.0% | 0.01% | +60.0% |
| Q4 2021 | $445,000 | -49.3% | 5,926 | -21.6% | 0.01% | -50.0% |
| Q3 2021 | $878,000 | -21.7% | 7,561 | +49.4% | 0.01% | -23.1% |
| Q2 2021 | $1,122,000 | +134.2% | 5,060 | +39.6% | 0.01% | +116.7% |
| Q1 2021 | $479,000 | -47.1% | 3,624 | -30.7% | 0.01% | -57.1% |
| Q4 2020 | $905,000 | +125.1% | 5,231 | -37.3% | 0.01% | +100.0% |
| Q1 2019 | $402,000 | +69.6% | 8,342 | +17.8% | 0.01% | +40.0% |
| Q4 2018 | $237,000 | -31.5% | 7,082 | +7.2% | 0.01% | -16.7% |
| Q3 2018 | $346,000 | +64.8% | 6,604 | -1.3% | 0.01% | +50.0% |
| Q2 2018 | $210,000 | – | 6,694 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Invus Financial Advisors, LLC | 350,884 | $77,833,000 | 15.51% |
| HARTLINE INVESTMENT CORP/ | 302,194 | $67,033,000 | 8.47% |
| Darsana Capital Partners LP | 700,000 | $155,274,000 | 4.42% |
| MORGAN JESS S & CO INC | 23,775 | $5,274,000 | 3.47% |
| Soleus Capital Management, L.P. | 98,975 | $21,955,000 | 3.38% |
| Montanaro Asset Management Ltd | 116,650 | $25,875,000 | 3.26% |
| Taylor Frigon Capital Management LLC | 31,035 | $6,884,000 | 2.15% |
| Rhenman & Partners Asset Management AB | 120,000 | $26,618,000 | 1.81% |
| COURAGE CAPITAL MANAGEMENT LLC | 10,000 | $2,218,000 | 1.33% |
| Derbend Asset Management | 5,789 | $1,284,000 | 1.20% |